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SUMMARY
Critically ill patients are at risk of developing both 
acute kidney injury (AKI) and invasive fungal infections 
(IFIs). Prompt and efficient treatment of the IFI is 
essential for the survival of the patient. This article 
examines three distinct clinical situations where 
liposomal amphotericin B, a broad- spectrum antifungal 
agent, was successfully used in the setting of AKI. 
The first was Aspergillus infection in a 63- year- old 
man with bleeding oesophageal varices related to 
advanced liver disease. The second was gastrointestinal 
mucormycosis in a 74- year- old man who developed 
a small bowel obstruction following an autologous 
stem cell transplant for mantle cell lymphoma. The 
third was a Fusarium infection in a 32- year- old woman 
on immunosuppression for a bilateral lung transplant 
for cystic fibrosis. In all three cases, liposomal 
amphotericin B was required for urgent management 
of the patient’s IFI. We discuss the rationale for 
treatment with a potentially nephrotoxic agent in this 
setting.
BACkgRoUnd
Critically ill patients are at risk of developing both 
acute kidney injury (AKI) and invasive fungal infec-
tions (IFIs).1 2 AKI is a syndrome with multiple 
aetiologies characterised by an abrupt decrease in 
kidney function and an associated major increase in 
mortality risk.1 Prompt treatment of the IFI is crit-
ical for patient survival,3 but full diagnostic infor-
mation is not always available to guide treatment 
choice. Empiric initiation of a broad- spectrum anti-
fungal agent may therefore be necessary.
Amphotericin B has a broad spectrum of activity 
against organisms causing IFIs, but is associated 
with nephrotoxicity.4 The liposomal formulation 
is less nephrotoxic than conventional amphoter-
icin B, but optimisation or maintenance of the 
patient’s renal function is an important consider-
ation during its use.5–7 Importantly, drugs should 
not be withheld for fear of nephrotoxicity if they 
are essential to achieve early control of sepsis and 
IFI.8
The three cases presented highlight the effective 
use of liposomal amphotericin B in patients with 
IFIs and AKI in different clinical scenarios.
CASe pReSenTATion
Case 1: fungal infection in a patient with 
advanced liver disease and Aki
Case presentation
A 63- year- old man presented to the accident and 
emergency department with haematemesis. At 
presentation, he was tachycardic and hypotensive, 
with clinical signs of ongoing bleeding and chronic 
liver disease, including ascites. Initial blood tests 
showed levels of haemoglobin at 73 g/L, platelets 
at 173×109 cells/L, sodium at 139 mmol/L and an 
international normalised ratio of 1.3. He was resus-
citated with intravenous fluids and transferred to 
the intensive care unit (ICU) where he received 
further fluid resuscitation, including a two- unit 
blood transfusion. Urgent endoscopy under general 
anaesthesia revealed bleeding oesophageal varices 
which were treated by sclerotherapy and banding. 
He was ventilated with an endotracheal tube and 
received ongoing fluid support and blood transfu-
sions. At day 3, he commenced prophylactic cipro-
floxacin to provide antibiotic cover against bacterial 
infections of unknown type, including potential 
spontaneous bacterial peritonitis caused by his 
ascites. From admission to day 3, his serum creat-
inine increased from 80 µmol/L to 159 µmol/L, 
indicating AKI stage 2, consistent with his haemo-
dynamic compromise in the setting of chronic liver 
disease. By day 7, the patient was showing clinical 
and haemodynamic improvements, but then devel-
oped a fever and became hypotensive. At this time, 
tests showed levels of haemoglobin at 94 g/L, plate-
lets at 225×109 cells/L, sodium at 132 mmol/L, 
serum creatinine at 133 µmol/L and C- reactive 
protein (CRP) at 45 mg/dL. Prompt investigation 
of the cause of the fever was imperative, given the 
patient’s critically ill state.
Investigations
A sepsis screen of blood, urine and sputum samples 
was carried out, and blood cultures grew an unspec-
ified fungus; subsequent plate culture and micros-
copy confirmed the presence of Aspergillus species. 
A transthoracic echocardiogram was normal, 
including an absence of heart valve lesions, and a 
CT scan of the chest did not indicate any typical 
changes consistent with aspergillosis, as shown in 
figure 1.
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Figure 1 CT scan showing opacification indicative of early acute 
respiratory distress syndrome but no features of aspergillosis.
Figure 2 Grocott methenamine silver stain of gastrointestinal lesion, 
showing mucormycosis in black.
Differential diagnoses
At the time of the fever, the patient was initially diagnosed with 
sepsis of unknown cause. The differential diagnosis was wide, 
including hospital- acquired pneumonia, line infection, urinary 
tract infection, spontaneous bacterial peritonitis, endocar-
ditis and pancreatitis. These possible diagnoses were excluded 
by carrying out organ- specific tests: urine cultures to rule out 
urinary tract infection, ascitic fluid cultures to rule out spon-
taneous bacterial peritonitis, blood tests and transthoracic 
echocardiogram to rule out endocarditis, amylase level tests to 
rule out pancreatitis, CT scan of the chest to rule out hospital- 
acquired pulmonary infection and renal ultrasound to exclude 
hydronephrosis.
Treatment
The fever was initially treated with broad- spectrum antibiotics 
(piperacillin/tazobactam and gentamicin), but the patient did not 
respond during 2 days of treatment. He developed worsening 
multiorgan failure, needing increasing vasopressor support and 
higher concentrations of oxygen to maintain adequate organ 
perfusion. Vancomycin was added empirically at day 9, and 
the central line changed in case it was the potential source of 
the infection. Following the growth of unspecified yeasts on 
day 10, liposomal amphotericin B at 3 mg/kg/day was added 
because of its broad spectrum of activity against a wide variety 
of fungal pathogens. The patient’s serum creatinine and CRP 
levels continued to rise and peaked at 273 µmol/L on day 13 and 
455 mg/L on day 11, respectively, but thereafter improved. He 
had a normal urine output throughout this period.
Outcome and follow-up
On day 12, the patient’s vasopressor support started decreasing 
and his oxygen requirements decreased from 60% to 45%. 
When Aspergillus species were identified as the causative agent 
at day 13, it was elected that the patient should continue on 
liposomal amphotericin B. On day 16, he was weaned off vaso-
pressor support. At day 33, he was discharged from the ICU. 
His serum creatinine returned to baseline levels and he was 
discharged home 2 weeks later. The level of kidney function 
change was consistent with the haemodynamic and septic status 
of the patient over the course of the illness. His continuing 
kidney function will depend on the status of his liver disease 
and future acute intercurrent illnesses. This patient will require 
ongoing, long- term monitoring of his kidney function.
Case 2: fungal infection in a patient with neutropenic sepsis 
and Aki
Case presentation
A 74- year- old man received an autologous stem cell transplant 
as part of treatment for mantle cell lymphoma. He had normal 
renal function prior to the transplant, but developed AKI stage 
2 immediately post- transplant, with a serum creatinine level of 
177 µmol/L. The cause of his AKI was thought to be multifacto-
rial, but mainly due to severe vomiting and norovirus diarrhoea. 
An ultrasound scan of his urinary tract was found to be normal. 
His renal function recovered to baseline and he was discharged 
from hospital.
Six weeks later, he was readmitted to hospital with persistent 
vomiting and constipation. His serum creatinine was 84 µmol/L. 
A CT scan showed evidence of small bowel obstruction and 
an emergency laparotomy was performed to diagnose and 
relieve the obstruction. One week later, the patient developed 
a high spiking fever and pancytopenia, and his serum creatinine 
increased to 181 µmol/L, due to a combination of neutropenic 
sepsis and probable volume depletion. To provide antimicro-
bial cover prior to a confirmed microbiological diagnosis of the 
causative agent, the patient was treated with piperacillin/tazo-
bactam and one dose of amikacin. Subsequent blood cultures 
grew Enterococcus faecium and vancomycin was added to the 
treatment regimen as a result. Vancomycin trough level measure-
ments were performed regularly, and his renal function remained 
stable. A resection of the small bowel stenosis was sent for histo-
logical analysis.
Investigations
Histology on the small bowel tissue identified gastrointestinal 
mucormycosis with angioinvasion, as shown in figure 2.
Differential diagnoses
Differential diagnoses on presentation included localised infec-
tion, including tuberculosis (TB) and cytomegalovirus, and 
tumours. The subsequent CT showed small bowel obstruction 
but no mass; therefore, a tumour or mass effect secondary to 
specific infections, such as TB, was of low likelihood.
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Figure 3 CT scan showing nodules (circled in red) and airway 
thickening (circled in blue).
Treatment
The patient was initiated on liposomal amphotericin B at 5 mg/
kg/day to treat the mucormycosis and received a 3- week course. 
Despite the concomitant use of one single dose of amikacin and 
a 2- week course of vancomycin, his renal function improved, 
with serum creatinine levels decreasing from 181 µmol/L to 
80 µmol/L. During this period, there was a focus on optimal 
maintenance of haemodynamic and fluid status, and not using 
avoidable nephrotoxic agents. The patient maintained his urine 
output throughout as a result of aggressive hydration treatment.
Outcome and follow-up
The patient was discharged on oral posaconazole for 3 months 
for mucormycosis treatment. He remained well, with no further 
episodes of fungal infection. After 1 year in remission, he suffered 
a relapse of his mantle cell lymphoma and died 10 months later.
Case 3: fungal infection in an immunocompromised patient 
with Aki
Case presentation
A 32- year- old woman underwent a bilateral lung transplant for 
cystic fibrosis, and required long- term, daily maintenance immu-
nosuppression including the calcineurin inhibitor tacrolimus. 
Thirteen months post- transplant, the patient presented in clinic 
with a productive cough and breathlessness, and a decrease in 
forced expiratory volume in 1 s (FEV1) from 2.35 L to 1.95 L; 
she was admitted to the ward. On admission, her serum creati-
nine level was normal at 75 µmol/L and she was taking prophy-
lactic oral posaconazole (gastro- resistant tablets) due to a history 
of aspergillosis, and long- term isavuconazole (hard capsules) due 
to previous Fusarium infection. A drop in FEV1, combined with 
clinical symptoms, mandated further investigation.
Investigations
A CT scan was performed, which indicated chest abnormali-
ties, as shown in figure 3. A bronchoscopy was carried out and 
culture of bronchoalveolar lavage fluid showed the presence of 
Fusarium and Elizabethkingia miricola.
Differential diagnoses
As the patient presented with a productive cough, a bacterial 
or fungal infection was suspected and further investigated using 
bronchoscopy. Histology obtained during the bronchoscopy 
showed interstitial changes with no evidence of obliterative 
bronchiolitis, suggesting that acute rejection of the lung trans-
plant was unlikely. Reverse- transcriptase PCR (RT- PCR) was 
used to investigate a panel of 14 respiratory viruses, including 
coronavirus OC43 infection, and nasopharyngeal aspirates 
(NPA) were collected to test for infection with respiratory syncy-
tial virus (RSV).
Treatment
On admission (day 0), the patient was immediately started on 
broad- spectrum antibiotics (piperacillin/tazobactam and tige-
cycline) to provide cover for suspected bacterial infections of 
unknown type. RT- PCR was negative for all 14 respiratory 
viruses, but NPA testing confirmed the presence of RSV; this was 
treated with methylprednisolone and ribavirin. On day 1, lipo-
somal amphotericin B at 3 mg/kg/day was started as treatment 
for Fusarium and the isavuconazole dosage was increased. She 
was discharged from hospital on day 13 but, due to progressive 
respiratory decline, continued to receive liposomal amphoter-
icin B at home, through a peripherally inserted central catheter. 
Her serum creatinine level rose throughout this period, peaking 
at 186 µmol/L on day 26, but this was managed by excluding 
obstruction, and optimising fluid and haemodynamic status.
Outcome and follow-up
A bronchoscopy was performed on day 27, which was reported 
as culture- negative. The patient remained well, with no further 
episodes of fungal infection, and her renal function recovered to 
normal levels, with no lasting impairment.
diSCUSSion
The Kidney Disease: Improving Global Outcomes guidelines 
recommend that exposure to nephrotoxic drugs should be 
limited in patients with or at risk of developing AKI, and that a 
risk/benefit assessment is carried out to weigh the risk of devel-
oping or worsening the AKI against the risk associated with not 
using the agent.1
IFIs are a major cause of death in critically ill patients, partic-
ularly in the setting of immunosuppression, such as following 
bone marrow transplantation or solid organ transplantation.2 
AKI in these patients is very common and can be associated with 
both sepsis itself and complications arising from its treatment.9 
In this clinical setting, it can be difficult to quantify the contri-
bution of individual components to a patient’s AKI. A careful 
assessment of the potential risk of a medication in the setting of 
AKI is essential. Paradoxically, in a critically ill patient, this may 
be a straightforward decision; if there is significant likelihood of 
an IFI, the patient will die without prompt treatment; therefore, 
commencement of antifungal therapy is essential. In all three 
cases reported here, prompt and efficient treatment of the IFI 
was critical to the survival of the patient and, therefore, the use 
of liposomal amphotericin B was deemed necessary. None of the 
patients experienced any lasting kidney damage as a result of 
this decision.
There are two specific clinical scenarios where the use of lipo-
somal amphotericin B should be considered. First, where there is 
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uncertainty around the species of the fungal agent in a critically 
ill patient and second, where the fungus is susceptible to ampho-
tericin B.
Delays between the clinical diagnosis of a likely IFI and confir-
mation of that diagnosis are common. Therefore, empirical treat-
ment with liposomal amphotericin B may be indicated, as this 
will provide broad- spectrum antifungal treatment against candi-
diasis, aspergillosis and mucormycosis, which can be resistant 
to other antifungals, such as certain azoles.10–12 It is important 
to continue to pursue a specific diagnosis after institution of 
liposomal amphotericin B. For example, if aspergillosis is subse-
quently confirmed, and there is a clear clinical requirement, then 
consideration may be given to switching to an alternative agent 
with narrow- spectrum efficacy and a lower incidence of renal 
complications than liposomal amphotericin B.
There is a long- standing recognition of the high risk of AKI 
in patients treated with conventional amphotericin B. In a large 
retrospective analysis carried out in 494 adult inpatients, 28% 
developed nephrotoxicity, defined as either a ≥50% increase 
from baseline or doubling of serum creatinine levels.13 Liposomal 
amphotericin B is substantially less nephrotoxic than conven-
tional amphotericin B; a meta- analysis reported nephrotox-
icity incidence rates of 14.5% and 32.5%, respectively.14 These 
differences in nephrotoxicity may reflect both the distribution 
and structure of the drugs; for example, liposomal amphoter-
icin B does not contain deoxycholate, which can cause direct 
renal tubular toxicity.15 Additionally, liposomal amphotericin B 
has been successfully used to treat IFIs in critically ill patients 
with impaired renal function at treatment initiation without 
adverse impact on renal function, as measured by serum creati-
nine levels.16 17
Patients with AKI who are receiving liposomal amphotericin 
B, or indeed any other drug with a potential effect on renal 
tubular function, should receive high- quality supportive care to 
maintain or restore the function of the distal tubular cells of the 
kidney. Optimal management of fluid balance and electrolytes 
and acid–base status is required. All electrolytes that are regu-
lated by the renal tubules should be monitored and replaced if 
below the normal range. It is important to replace all depleted 
electrolytes as, for example, replacement of potassium in a 
patient who is hypomagnesaemic and/or hypophosphataemic (or 
vice versa) without replacing magnesium and/or phosphate will 
not help the underlying tubular deficit. Metabolic acidosis can 
be corrected through the administration of bicarbonate, which 
is best given as an isotonic solution. With accurate monitoring 
and supplementation, the majority of patients should be able to 
continue on their course of liposomal amphotericin B.
While there are several, recently published cases describing 
the successful use of liposomal amphotericin B in the treatment 
of various IFIs,18–20 to our knowledge, this is the first case series 
to specifically examine its use in patients with AKI. Each case 
illustrates a clinical course of improvement and recovery while 
the patient was on treatment with liposomal amphotericin B. In 
our experience, AKI is a frequent consideration in prescribing of 
antifungal agents in the critically ill patient. These cases there-
fore allow us to explore the decision- making processes for the 
use of antifungal agents in this setting. We believe that there are 
clear signposts on how to use liposomal amphotericin B in the 
setting of AKI. These comprise:
1. Ensuring that the presence of an IFI is considered in all crit-
ically ill patients.
2. If a patient commences treatment on clinical grounds alone, 
tests to establish a diagnosis of the agent causing the IFI 
should continue.
3. AKI is not a contraindication to commencing treatment with 
liposomal amphotericin B where there is a clinical diagnosis 
of a potential life- threatening IFI.
4. A discussion around the risk/benefit of starting liposomal 
amphotericin B should take place both within the clinical 
team and with the patient and/or their next of kin. This dis-
cussion should be carefully documented.
5. The patient should receive appropriate supportive care to 
optimise their kidney function, which should be monitored 
daily.
6. Further formal risk/benefit assessments should be carried out 
in the event of:
i. worsening AKI.
ii. microbiological confirmation of the causative agent.
In conclusion, while there is no published literature to provide 
evidence for practice, AKI and IFI are common in critically ill 
patients. Our case studies indicate that the use of liposomal 
amphotericin B to treat IFIs in critically ill patients with AKI 
may be indicated where the fungal species is unknown or where 
susceptibility to amphotericin B is known. With prompt treat-
ment with liposomal amphotericin B, alongside high- quality 
supportive care, good clinical outcomes can be achieved.
Learning points
 ► Acute kidney injury (AKI) and invasive fungal infections (IFIs) 
are common in critically sick patients, and both should be key 
considerations during the management of such patients.
 ► Prompt treatment of the IFI is critical to patient survival.
 ► A careful, documented assessment of the potential risk of a 
medication in the setting of AKI is essential.
 ► Liposomal amphotericin B to treat IFIs in critically sick 
patients with AKI may be indicated where the fungal species 
is unknown or where susceptibility to amphotericin B is 
known.
 ► It is important to continue to pursue a specific diagnosis after 
the institution of liposomal amphotericin B.
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